Fri Sep 27 14:38:59 UTC 2024: ## Torrent Pharma Shares Rise After Refuting Shelcal 500 Quality Test Failure
**Mumbai, India -** Torrent Pharmaceuticals shares saw a slight increase on September 27th following the company’s strong denial of a quality test failure for their Shelcal 500 product. The Central Drug Standards Control Organization (CDSCO) had listed Shelcal 500, along with over 50 other drugs, as “Not of Standard Quality” in their August 2024 drug alert.
However, Torrent Pharma has asserted that the sample of Shelcal 500 seized by CDSCO was not manufactured by them and is, in fact, a spurious product. Their investigation, conducted to verify the sample’s authenticity, revealed that the batch details did not match those of legitimate Torrent products.
Torrent has further emphasized the use of QR tags on their products to ensure authenticity, a feature missing from the confiscated samples. The company has submitted their findings and assessment report to CDSCO.
The CDSCO’s “not of standard quality” list also includes other well-known pharmaceuticals like Glimepiride, Pan D, and Telmisartan.
Despite the CDSCO’s findings, Torrent Pharma’s shares were trading 0.03% higher at Rs 3,413.45 on NSE at 12:32 pm.
First Piper 